ERBB2 and neoplasm: Moreover, another study demonstrated 98.4% overall concordance (248/252) between NGS-detected HER-2 amplification and IHC/FISH results in breast and gastroesophageal adenocarcinomas, with discrepancies mostly occurring in cases of low tumor content or HER-2 heterogeneity (20).